首页|期刊导航|西南医科大学学报|阿替普酶联合尤瑞克林治疗心源性急性脑梗死回顾性队列研究

阿替普酶联合尤瑞克林治疗心源性急性脑梗死回顾性队列研究OA

Retrospective Cohort Study of Alteplase Combined with Urinary Kallidinogenase in the Treatment of Cardiogenic Acute Cerebral Infarction

中文摘要英文摘要

目的 探讨阿替普酶(rt-PA)联合尤瑞克林治疗心源性急性脑梗死的临床效果.方法 收集2021年1月至2025年1月河南省漯河市中心医院收治的127例心源性急性脑梗死住院患者的病历资料,所有患者均完成完整的配套检查与治疗.根据治疗方案分成对照组62例(单用rt-PA)和研究组65例(rt-PA联合尤瑞克林).比较两组患者的基线资料、血液流变学指标[全血低切黏度、全血高切黏度、纤维蛋白原(FIB)]、颅脑超声指标[大脑中动脉(MCA)、椎动脉(VA)和基底动脉(BA)的脑血流流速]和实验室相关指标[血清同型半胱氨酸(Hcy)、血管内皮生长因子(VEGF)、可溶性细胞间黏附分子-1(sICAM-1)]水平,并评估两组临床疗效与安全性.结果 治疗14 d后研究组NIHSS评分低于对照组[(7.68±2.04)分 vs.(9.01±2.16)分],NIHSS减分率高于对照组[(50.29±6.21)%vs.(41.76±5.85)%],疗效等级优于对照组,差异均有统计学意义(P<0.05).随访3个月,研究组预后良好率为80.00%(52/65),高于对照组的62.90%(39/62),差异有统计学意义(P<0.05).治疗14 d后,研究组全血低切黏度、全血高切黏度和FIB水平均低于对照组,MCA、VA和BA脑血流流速均高于对照组,差异有统计学意义(P<0.05).研究组血清Hcy和sICAM-1水平低于对照组,VEGF水平高于对照组,差异均有统计学意义(P<0.05).两组出血事件发生率比较,差异无统计学意义(P>0.05).结论 rt-PA联合尤瑞克林治疗心源性急性脑梗死临床疗效确切且安全性较好,可显著改善患者神经功能及预后.其机制可能与改善血液流变学,促进颅脑血流循环和调节Hcy、VEGF和sICAM-1表达有关.

Objective To explore the therapeutic effect of Alteplase(rt-PA)combined with Urinary Kallidinogenase on cardio-genic acute cerebral infarction.Methods Medical records of 127 inpatients with cardiogenic acute cerebral infarction admitted to Luohe Central Hospital,Henan Province from January 2021 to January 2025 were collected.Complete supporting examination and treatment data were retained in all cases.According to different treatment plans,the patients were divided into the rt-PA group(using rt-PA alone)and the study group(rt-PA combined with Urinary Kallidinogenase),with 62 and 65 cases respectively.The levels of baseline data,hemorheology[low shear viscosity of whole blood,high shear viscosity of whole blood,fibrinogen(FIB)],cranial ultra-sound indicators[cerebral blood flow velocity of the middle cerebral artery(MCA),vertebral artery(VA),and basilar artery(BA)]and laboratory-related indicators[serum homocysteine(Hcy),vascular endothelial growth factor(VEGF),soluble intercellular adhe-sion molecule-1(sICAM-1)]were compared,and the clinical efficacy and safety indicators of the two groups were evaluated.Results After 14 days of treatment,the NIHSS score of the study group[(7.68±2.04)points vs.(9.01±2.16)points]was lower than that of the rt-PA group,and the NIHSS reduction rate[(50.29±6.21)%vs.(41.76±5.85)%]was higher than that of the rt-PA group.The thera-peutic effect grade was better than that of the rt-PA group.The differences were all statistically significant.At the end of the 3-month follow-up,the good prognosis rate of the study group was 80.00%(52/65),which was higher than that of the control group 62.90%(39/62),and the difference was statistically significant.After 14 days of treatment,the low shear viscosity,high shear viscosity and FIB of whole blood in the study group were all lower than those in the rt-PA group,and the cerebral blood flow velocities of MCA,VA and BA were all higher than those in the rt-PA group.The differences were statistically significant.After 14 days of treatment,the levels of serum Hcy and sICAM-1 in the study group were lower than those in the rt-PA group,and VEGF was higher than that in the rt-PA group.The differences were statistically significant.There was no statistically significant difference in the incidence of bleeding events between the two groups.Conclusion rt-PA combined with Urinary Kallidinogenase has a good clinical efficacy and safety in the treatment of cardiogenic acute cerebral infarction.It can improve the neurological function and prognosis of patients.The mechanism may involve improving hemorheology,promoting cerebral blood circulation,and regulating Hcy,VEGF,and sICAM-1 expression.

朱磊;黄圣明;韩丽;孙若晗

漯河市中心医院 神经内科(漯河 462000)漯河市中心医院 神经内科(漯河 462000)漯河市中心医院 神经内科(漯河 462000)哈尔滨医科大学附属第一医院 神经内科(哈尔滨 150000)

医药卫生

心源性急性脑梗死阿替普酶尤瑞克林脑血流血液流变学神经功能

Cardiogenic acute cerebral infarctionAlteplaseUrinary KallidinogenaseCerebral blood flowHemorheologyNeural function

《西南医科大学学报》 2026 (4)

461-466,6

国家自然科学基金(82001131)河南省联合科技攻关项目(LHGJ20191412)

10.3969/j.issn.2096-3351.2026.04.008

评论